

An optimised protocol for detection of SARS-CoV-2 in stool

3 Li T^{1,#}, Garcia-Gutierrez E^{1,#}, Scadden J¹, Davies J¹, Hutchins C¹, Aydin A², Romano S^{1,*},
Sayavedra L^{1,*}, O'Grady J² and Narbad A¹

¹Gut Health and Microbes, Quadram Institute Bioscience, Norwich Research Park, Norwich, United
6 Kingdom

²Microbes in the Food Chain, Quadram Institute Bioscience, Norwich Research Park, Norwich,
United Kingdom

9 #Equal contribution

*Address correspondence to Lizbeth.Sayavedra@quadram.ac.uk, Stefano.Romano@quadram.ac.uk

12 **Short title:** An optimised protocol for detection of SARS-CoV-2 in stool

15

18

Keywords: FMT; COVID19; RT-qPCR; stool; clinical-test

21

Grant Support This work was supported by funding from the QIB, the Biotechnology and
Biological Sciences Research Council (BBSRC) Impact Accelerator Account (BB/S506679/1),
24 Institute Strategic Programme Gut Microbes and Health (BB/R012490/1) and its constituent
projects BBS/E/F/000PR10355 and BBS/E/F/000PR10356, Institute Strategic Programme Microbes
in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348,
27 BBS/E/F/000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352.

Disclosures The authors declare that there are no conflicts of interest

30

Abstract

33 **Aim:** SARS-CoV-2 has been detected in stool samples of COVID-19 patients, with potential
implications for faecal-oral transmission. Compared to swab samples, the complexity of the stool
matrix poses a challenge in the detection of the virus that has not yet been solved. The aim of this
36 study was to establish a sensitive and reliable method for detecting SARS-CoV-2 in stool samples.

Methods: Stool samples from individuals free of SARS-CoV-2 were homogenised in saline buffer
and spiked with a known titre of inactivated virus ranging from 50 to 750 viral particles per 100 mg
39 stool. Debris was removed via centrifugation and supernatants were concentrated by ultrafiltration.
RNA was then extracted from the concentrated material using a commercial kit and SARS-CoV-2
was detected via real-time reverse-transcription polymerase chain reaction (RT-qPCR) using the
42 CDC primers and probes.

Results: The RNA extraction procedure we used allowed the detection of SARS-CoV-2 via RT-
qPCR in most of the stool samples tested. We could detect as few as 50 viral particles per 100 mg of
45 stool. However, high variability was observed across samples at low viral titres. The primer set
targeting the N1 region provided more reliable and precise results and for this primer set our
method had a limit of detection of 1 viral particle per mg of stool.

48 **Conclusions:** Here we describe a sensitive method for detecting SARS-CoV-2 in stool samples.
This method can be used to establish the persistence of SARS-CoV-2 in stool and ensure the safety
of clinical practices such as faecal microbiota transplant (FMT).

51

54

57

60

1. Introduction

63 The COVID-19 global pandemic, caused by SARS-CoV-2, poses an imminent threat to the global
population. From December 2019 until the 16th of December 2020, the number of confirmed cases
stands at 72.7 million and rising, leading to an unprecedented challenge on health systems
66 internationally. SARS-CoV-2 causes severe acute respiratory syndrome - infecting human cells by
binding to the receptor angiotensin converting enzyme 2 (ACE2). ACE2 is an inflammation
regulator on the epithelial cells of the lung, liver, and gastrointestinal tract ^{1,2}. It has been reported
69 that gastrointestinal symptoms, such as diarrhoea, nausea, and vomiting, may be observed in up to
61% of cases ³. These gastrointestinal symptoms may be linked to the severity of the COVID-19
disease based on viral load and degree of viral replication in the gut ³⁻⁶. SARS-CoV-2 RNA has been
72 detected in the stool during infection, as well as when the patients have apparently recovered, and
the nasal swab is negative ⁷. Viable SARS-CoV-2 has been isolated from stool samples ⁷⁻⁹, which
suggests that there is a potential risk of faecal-oral transmission ¹⁰⁻¹⁴. Hence, monitoring the viral
75 load in stool is of crucial importance to maintain public health and limit viral spreading. A few
studies have reported that the viral load in stool samples (10^2 - 10^7 genome copies mL^{-1}) is several
orders of magnitude lower than in saliva (10^8 genome copies mL^{-1}) ^{15,16}. However, methods for the
78 detection of the virus in stool have been poorly described. Robust and reliable methods are an
urgent need, as microbiota-based therapies such as faecal microbiota transplantation (FMT) would
need to rely heavily on the accurate screening of donor stools to ensure the absence of SARS-CoV-2
81 and guarantee patient safety ¹⁷.

For nasal swabs and saliva samples, RT-qPCR is the most used diagnostic tool for detecting SARS-
84 CoV-2, with many assays targeting the SARS-CoV-2 nucleocapsid (N) gene ^{18,19}. The commonly
used Center for Disease Control and Prevention (CDC) test targets two regions of the N gene (N1
and N2). However, the faecal matrix has properties distinct from those of respiratory samples ²⁰⁻²²
87 and this makes the reliable detection of SARS-CoV-2 challenging. Recently, a few methods have
been described for the detection of SARS-CoV2 in stool samples ^{17,23,24}. However, the potentially
low concentration of SARS-CoV2 in faeces and the unique features of the sample matrix require
90 optimized protocols to improve the recovery of viral RNA and increase our ability to detect the
virus in stool samples. To address this need, we developed a reliable and sensitive method for
SARS-CoV-2 detection in stool.

96 2. Methods

2.1. Sample preparation and RNA extraction

Stool samples collected either before the COVID-19 outbreak (October 2019), or from donors who
99 did not display and had not displayed symptoms of COVID-19 were weighed (100 mg) and
homogenised in saline solution (0.89% w:v NaCl) with a ratio of 1:10 (w:v; 100 mg in 1 mL) by
vortexing for at least 1 minute. In an initial screening phase, we assessed the effect of an
102 ultrafiltration step aimed at enriching viral particles (vp) before RNA extraction using a single stool
sample. For these tests, we spiked the homogenised stool with different volumes of AMPLIRUN®
TOTAL SARS-CoV-2 CONTROL (VirCell Microbiologists, Spain) and then either directly
105 extracted RNA using the QIAamp Viral RNA Mini Kit (Qiagen, UK; CN 52906) or first enriched
the viral particles by ultrafiltration and then extracted the RNA, as described below. Since the
ultrafiltration step improved SARS-CoV-2 detection we added this step in all further RNA
108 extractions.

All the following experiments were performed by spiking the homogenised stool samples with the
111 inactivated stock solution of SARS-CoV-2 positive Q control, SCV2QC01-B, Qnostics (UK). We
used this stock because it has been precisely quantified by the manufacturing company using digital
PCR. The stock is available by the supplier (Randox Biosciences, UK) in transport media at a viral
114 concentration of 10,000 digital copies (dC) mL⁻¹. The homogenised stool samples (1 mL) were
spiked with different concentrations of viral particles, centrifuged at 4,000 g for 10 minutes, and
then supernatants were filtered through 0.22 µm syringe filters. Virus enrichments were then
117 performed using ultrafiltration tubes (Sigma, UK; CN UFC810024) by loading 500 µl of the filtrate
and centrifuging at 2,500 g for 10 minutes. The concentrated samples (around 50 µl) were used for
RNA extraction using QIAamp Viral RNA Mini Kit, following the protocol provided by the
120 manufacturer. Finally, the viral RNA was eluted in two aliquots of 40 µl buffer AVE supplied with
the kit as recommended by the manufacturer to increase the yield. An overview of the method we
developed is reported in Fig 1A. We first used three stool samples to assess the lowest amount of
123 virus detectable with our approach. The same samples were then used to assess the effect of the
solution used to homogenise the stool (Table 1). This was done by repeating the above protocol and
homogenising the stool not in saline solution but in AVL Buffer (Qiagen, UK; CN 19089), as
126 recommended in the QIAamp Viral RNA Mini Kit manufacturer manual. 24 additional stool
samples were then used to verify the variability of the assay across stool types and to infer the
sensitivity and specificity of our protocol by extracting RNA after spiking them with 0, 100 and 200
129 vp per 100 mg. Finally, an additional stool sample was used to calculate the limit of detection (LoD)
of our method. An overview of the experiments performed in this study is reported in Fig 1B.

The LoD, defined as the lowest concentration of virus at which all samples had at least one positive
132 RT-qPCR replicate, was estimated as follows. A freshly collected stool sample was diluted in saline
solution in the ratio specified above and then stored at -20° C until further processing. After
thawing, the homogenised stool sample was aliquoted and six and seven replicates were spiked with
135 100 and 200 vp per 100 mg, respectively. Six non-spiked replicates were also prepared. Samples
were processed as described, and virus enrichment was performed using between 500 and 600 µl of
supernatant. RNA was extracted as described. To verify the absence of contamination in the
138 reagents, we also performed RNA extractions using kit reagents only. Finally, as positive control,
we extracted RNA from 10 µL of the original stock used to spike the samples.

141 .




Figure 1 | A) Overview of our optimised method for SARS-CoV-2 detection in stool samples. **B)**
144 Schematic representation of the experiments conducted.

2.2. RT-qPCR assay

147 Primer sets N1 and N2 (Integrated DNA Technologies, Belgium, 10006713) were used for
identifying SARS-CoV-2 with the Probe 1-Step Go No Rox or Probe 1-Step Go Rox kits (PCR

Biosystems)²⁵. RT-qPCR was then performed in a Roche LightCycler® 480 Instrument II or a
150 StepOnePlus™ Real-Time PCR System (Applied Biosystems™) using the following conditions: 50
°C 10 min, 95 °C for 2 min, 45 cycles of 95 °C 5 s, 55 °C 30 s, followed by 40 °C 30 s. The Ct
values were calculated and samples were considered as positive only if they showed Ct lower than
153 40 cycles. RT-qPCR was always performed using two technical replicates. As the aim of this study
was to verify the variability in detecting SARS-CoV-2 in stool samples with the intention of
reporting robust guidelines for screening FMT material, we considered positive also samples for
156 which only 1 RT-qPCR technical replicate gave positive amplification. To determine the 95%
confidence interval for the specificity and the sensitivity we used the *binom.test* function in the R
software²⁶.

159

3. Results

Several recent studies indicate that viable SARS-CoV-2 can be detected in stool samples of
162 COVID-19 patients^{7,8}, suggesting that a possible risk for faecal-oral transmission exists. However,
methods for the detection of SARS-CoV-2 in stool have been poorly assessed so far, and an
optimized protocol is currently missing. Here, we describe an optimized protocol (Figure 1A) to
165 improve the detection of SARS-CoV-2 in stool samples. We performed our experiments using
samples collected either before the current pandemic started (October 2019) or from healthy donors
who did not display and had not displayed symptoms of COVID-19. We used a commercially
168 available SARS-CoV-2 stock, which was quantified using digital PCR by the manufacturer and was
therefore used to infer the limit of detection of our approach. The extracted RNA samples were then
used to detect SARS-CoV-2 via RT-qPCR with primer sets N1 and N2 using established protocols
171²⁵. We assessed how various steps throughout the RNA extraction influence the detection of SARS-
CoV-2 in stool and report recommendations for optimizing these procedures in future clinical
settings.

174

First, we spiked different volumes of an inactivated viral stock in stool samples and extracted the
RNA with or without ultrafiltration (Supplementary Table 1). We obtained positive amplifications
177 for both the N1 and N2 regions using both approaches. Without ultrafiltration we obtained positive
amplifications with both N1 and N2 primer sets down to 2900 vp per 100 mg. In contrast, the
addition of ultrafiltration allowed us to detect positive amplifications with both primer sets down to
180 725 vp per 100 mg (Supplementary Table 1). Hence, for all further tests we included an
ultrafiltration step in our protocol. We then wanted to assess what viral concentration was more
reliably detected across stool types. Thus, we used a viral stock that had been accurately quantified


183 using digital PCR and we spiked three stool samples using concentrations ranging from 0 to 750 vp
per 100 mg. We were able to detect SARS-CoV-2 in all stool samples we tested. The lowest
concentration we could detect was 50 vp per 100 mg (Table 1), but a high variability amongst
186 samples was observed for the lower concentrations (50-200 vp per 100 mg). This variability might
be the result of the stool characteristics, for example, mucus and fibre content, as it has been
previously reported that stool features can inhibit molecular assays ²⁰⁻²².

189

We then selected the two lowest concentrations that gave reliable results (100 and 200 vp per 100
mg) to estimate the limit of detection (LoD) of our method. The stool sample used to determine the
192 LoD was exclusively used for this experiment (i.e. was not used to create the previous datasets). We
performed repeated extractions after spiking the homogenized stool sample with 100 vp per 100 mg
(6 replicates in total) and 200 vp per 100 mg (7 replicates in total). As negative control, we also
195 extracted 6 non-spiked stool aliquotes all of which resulted negative in the RT-qPCR assay. For the
N1 primer set all samples spiked with either 100 or 200 vp per 100 mg resulted positive in the RT-
qPCR assay (Table 2). For the N2 primer set instead, 3 out of 6 and 7 out of 7 samples gave positive
198 amplification for the 100 and 200 vp per 100 mg spikes, respectively (Table 2). Based on this data
our approach has a LoD, defined as the lowest concentration at which all tested samples gave
positive results in at least one RT-qPCR replicate, of 100 vp per 100 mg (1 vp mg^{-1}) for the N1
201 primer set and 200 vp per 100 mg (2 vp mg^{-1}) for the N2 primer set. These data are consistent with
previous reports that highlighted the higher sensitivity of the N1 assay compared to the N2 assay ²⁷.
This LoD corresponds to 1000 vp g^{-1} for N1 and 2000 vp g^{-1} for N2 and to the best of our
204 knowledge is the lowest LoD so far described ^{17,24}. It is worth noting that for practical reasons we
took roughly half of the initial faecal slurry for RNA extraction (500-600 μL of the 1 mL in which
100 mg stool was homogenised). Hence, the Ct values we obtained are from roughly half the initial
207 number of viral particles spiked, if we assume an homogeneous suspension. Moreover, following
the recommendation in the RNA extraction kit manufacture's protocol we eluted the extract twice
with 40 μL buffer. Although the elution with this volume ($2 \times 40 \mu\text{L}$) might increase the total yield
210 of RNA, an elution with lower volume could result in a more concentrated extract and therefore,
increase the sensitivity of the RT-qPCR assay. Therefore, we believe that our method has room for
further improvements by enhancing the separation between debris and supernatant to recover higher
213 fractions of the slurry used in the RNA extraction and by using smaller volumes for RNA elution.

Finally, we tested our method on 24 additional stool samples to estimate the variability in detection
216 deriving by stool type and infer the specificity and sensitivity of our assay. We were able to detect

the virus reproducibly and consistently across the majority of the samples with average Ct values ranging from 32.6 to 38.2 and from 31.4 to 37.9 for the N1 and N2 regions, respectively (Figure 2).
219 Using these 24 samples we estimated that our method has a sensitivity of 100% for both the N1 and N2 primer set, and a specificity of 96% and 92% for the N1 and N2 primer sets, respectively (Table 3). The false-positive results might derive from contamination that occurred during sample
222 preparation or could be a consequence of the virus enrichment in our protocol. Stool samples contain a high diversity of mostly uncharacterized viruses ²⁸, and RNA viruses are among the lesser known viruses within the human virome ²⁹. Hence, by enriching viral particles we increase the
225 chances of extracting RNA from novel viruses that might be unspecifically amplified in the RT-qPCR assay, leading to false-positive results. Additional tests are needed to verify this hypothesis.



228 **Figure 2** | Ct values obtained for the N1 and N2 regions used to detect SARS-nCoV-2 in stool samples. Only data for the samples spiked with 100 vp per 100 mg are reported. In five samples only one replicate gave positive results, which have been included in the graphs.

231

We consistently detected viral particles in stool samples diluted in saline buffer. We then tested whether homogenising the faecal material in the Qiagen AVL lysis buffer instead of saline buffer
234 might affect RNA recovery. For this additional test, we used the same three stool samples initially used to assess the lowest viral load detectable, but homogenised them in Qiagen AVL buffer. When we used the Qiagen AVL buffer a higher variability was observed across samples (Table 1). We
237 observed that the faecal material does not fully homogenise in the lysis buffer (Supplementary Figure 1), suggesting that this might potentially affect the release of viral particles from the stool

matrix. This observation is particularly relevant because in several studies RNA has been extracted
240 from stool samples by applying the standard manufacturers' protocol of the extraction kits^{14,30}.
These are not necessarily optimized for stool and recommend dissolving samples in the extraction
buffer (e.g. Qiagen AVL buffer). Our data indicate that depending on the stool matrix type, this
243 procedure can reduce the efficiency of the RNA extraction and possibly underestimate the virus
detection.

246 **4. Conclusions**

Here we assess the technical challenges encountered while screening stool material for the presence
of SARS-CoV-2. We describe a robust approach to detect SARS-CoV-2 in stool samples, having an
249 LoD of 1 and 2 vp mg⁻¹ for the N1 and N2 primer set, respectively. Although we could detect as low
as 50 vp per 100 mg, a high variability can be observed between stool sample types when viral
concentrations are low. We demonstrated that following manufacturer's RNA extraction protocols
252 may not be sufficient to detect SARS-CoV-2 in stool samples as stool consistency and
homogenisation media can affect the downstream assays. To improve detection, we suggest to
homogenise the stool samples in saline solution first, then concentrate the viral particles with
255 ultrafiltration. Our method is sufficiently reliable to monitor the prevalence and persistence of the
viral particles in the gut and can help in determining the safety of samples intended for use in FMT
applications. To ensure the maximal safety for the patients, we propose that FMT donors should be
258 screened following the recommendations here, and donor stool should be excluded even if a single
N region (N1 or N2) or a single replicate per region gives a positive result due to the variability
introduced by the stool matrix.

261

Table 1 | Ct values of RT-qPCR using RNA extracted from sample homogenised in saline buffer and AVL buffer

Viral load ^a	Saline buffer						AVL buffer					
	Stool 1		Stool 2		Stool 3		Stool 1		Stool 2		Stool 3	
	N1-mean	N2-mean	N1-mean	N2-mean	N1-mean	N2-mean	N1-mean	N2-mean	N1-mean	N2-mean	N1-mean	N2-mean
0	-	-	-	-	-	-	-	-	-	-	-	-
50	34.8	36.2	-	-	-	33.5	35.2	-	-	-	-	-
100	34.8	36.3	-	-	34.2	32.5	34.9	35.2	-	-	-	-
150	34.6	35.3	35.8	-	34.9	33.9	33.8	34.7	36.4	-	-	-
200	34.2	34.0	35.9	-	34.2	33.0	33.5	33.9	35.8	-	37.2	-
250	34.0	34.6	35.4	-	34.8	33.6	35.0	36.0	36.7	-	36.0	-
500	32.8	33.6	34.2	-	33.7	33.5	35.1	36.3	36.2	-	35.4	36.7
750	32.7	33.7	35.4	33.8	33.5	33.9	36.0	-	36.6	-	33.1	34.8

264 ^aNumbers of viral particles spiked in 100 mg of stool
 - = Sample showed no Ct value

267

Table 2 | Overview of the limit of detected (LoD) experiments

	N1		N2	
	100	200	100	200
Viral particles in 100 mg				
Number of replicates	6	7	6	7
SARS-CoV-2 positive^a	6 (100%)	7 (100%)	3 (50%)	7 (100%)
Mean Ct (st. dev)	32.6 (±0.8)	31.4 (±0.5)	32.8 (±0.4)	32.1 (±0.5)

^a Samples were considered positive if at least one RT-qPCR replicate showed Ct values < 40.

270

273 **Table 3** | Sensitivity and specificity of the protocol we developed. Data refer to the 24 stool samples spiked with 100 viral particles per 100 mg. The 95% confidence interval is reported in brackets. A sample is considered positive if a single RT-qPCR replicate with Ct < 40 is detected for either the N1 or N2 primer set.

Regions of N gene amplified	Sensitivity (N = 24)	Specificity (N = 24)
N1	24/24 (100%, CI = 86-100)	23/24 (96%, CI = 79-100)
N2	24/24 (100%, CI = 86-100)	22/24 (92%, CI = 73-99)

276

279

282 **Acknowledgements**

We thank Emma Flannagan and Dr David Vauzour for providing samples, Lee Kellingray, George Savva, and Sharlize Pedroza-Matute for fruitful discussions and Gemma Kay for provision of
285 reagents. This work was supported by funding from the QIB, the Biotechnology and Biological Sciences Research Council (BBSRC) Impact Accelerator Account (BB/S506679/1), Institute Strategic Programme Gut Microbes and Health (BB/R012490/1) and its constituent projects
288 BBS/E/F/000PR10355 and BBS/E/F/000PR10356, Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352.

291

Ethics statement

Faecal samples were provided by different donors either via the NRP Biorepository from a study
294 approved by the Ethical Review Committee of the University of East Anglia, Norwich (R204719) registered at <http://www.clinicaltrials.gov/> (NCT03679533) or by a study approved by the QIB Human Research Governance committee (IFR01/2015) and registered at
297 <http://www.clinicaltrials.gov/> (NCT02653001).

References

1. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. *Nature* 2012;487:477-481.
2. Zhang H, Kang Z, Gong H, et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. *Gut* 2020;69:1010-1018.
3. Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: more than meets the eye. *Gut* 2020;69:973-974.
4. Gou W, Fu Y, Yue L, et al. Gut Microbiota May Underlie the Predisposition of Healthy Individuals to COVID-19. *Public and Global Health*, 2020. <http://medrxiv.org/lookup/doi/10.1101/2020.04.22.20076091>. Accessed April 27, 2020.
5. Henry BM, de Oliveira MHS, Benoit J, et al. Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. *Intern Emerg Med* 2020;15:857-859.
6. Jin X, Lian J-S, Hu J-H, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut* 2020;69:1002-1009.

7. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* March 2020.
8. Amirian ES. Potential fecal transmission of SARS-CoV-2: Current evidence and implications for public health. *Int J Infect Dis* 2020;95:363-370.
9. Zhang Y, Chen C, Song Y, et al. Excretion of SARS-CoV-2 through faecal specimens. *Emerg Microbes Infect* 2020;9:2501-2508.
10. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* January 2020.
11. Yao XH, Li TY, He ZC, et al. [A pathological report of three COVID-19 cases by minimal invasive autopsies]. *Zhonghua Bing Li Xue Za Zhi* 2020;49:411-417.
12. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465-469.
13. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect* 2020;9:386-389.
14. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020;5:434-435.
15. Jones D, Quintela Baluja M, Graham D, et al. Fecal Shedding of SARS-CoV-2 and Its Potential Role in Person-To-Person Transmission and the Environment-Based Spread of COVID-19. *LIFE SCIENCES*, 2020. <https://www.preprints.org/manuscript/202007.0471/v1>. Accessed September 22, 2020.
16. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020;20:565-574.
17. Ng SC, Chan FKL, Chan PKS. Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification. *Lancet Gastroenterol Hepatol* 2020;5:642-643.
18. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 2020;25:2000045.
19. Loeffelholz MJ, Tang Y-W. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. *Emerg Microbes Infect* 2020;9:747-756.
20. Acharya KR, Dhand NK, Whittington RJ, et al. PCR Inhibition of a Quantitative PCR for Detection of *Mycobacterium avium* Subspecies *Paratuberculosis* DNA in Feces: Diagnostic Implications and Potential Solutions. *Front Microbiol* 2017;8.
21. Monteiro L, Bonnemaïson D, Vekris A, et al. Complex polysaccharides as PCR inhibitors in feces: *Helicobacter pylori* model. *J Clin Microbiol* 1997;35:995-998.
22. Oikarinen S, Tauriainen S, Viskari H, et al. PCR inhibition in stool samples in relation to age of infants. *J Clin Virol* 2009;44:211-214.

23. Perchetti GA, Nalla AK, Huang M-L, et al. Validation of SARS-CoV-2 detection across multiple specimen types. *J Clin Virol* 2020;128:104438.
24. Coryell MP, Iakiviak M, Pereira N, et al. Validation and testing of a method for detection of SARS-CoV-2 RNA in healthy human stool. *medRxiv* November 2020:2020.11.09.20228601.
25. Centers for Disease Control and Prevention. DC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. 2020.
26. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2019. <https://www.R-project.org/>.
27. Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. *Nat Microbiol* 2020;5:1299-1305.
28. Aggarwala V, Liang G, Bushman FD. Viral communities of the human gut: metagenomic analysis of composition and dynamics. *Mob DNA* 2017;8:12.
29. Gregory AC, Zablocki O, Zayed AA, et al. The Gut Virome Database Reveals Age-Dependent Patterns of Virome Diversity in the Human Gut. *Cell Host Microbe* 2020;28:724-740.e8.
30. Zuo T, Liu Q, Zhang F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. *Gut* July 2020.

Supplementary materials

Supplementary Figure 1 | Faecal samples mixed and resuspended in 1 mL of saline buffer (left) resulted in a better homogenisation of the stool as compared to using AVL buffer (right).



Supplementary Table 1 | Ct values obtained from stool samples spiked with different amounts of viral particles used to extract RNA with or without ultrafiltration.

Spiked viral particles (vp in 100 mg)	Without ultrafiltration				With ultrafiltration			
	N1	N1	N2	N2	N1	N1	N2	N2
2900	32.3	31.9	31.4	31.3	nt	nt	nt	nt
1450	32.6	33.6	-	-	32.7	32.6	31.3	31.6
725	nt	nt	nt	nt	33.2	32.5	33.5	33.6

nt = not tested

- = Sample showed no Ct value